2015
The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers.
Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets 2015, 15: 652-64. PMID: 26452382, DOI: 10.2174/156800961508151001101209.Peer-Reviewed Original ResearchConceptsBreast cancerPredictive markerImmune cellsStromal componentsHER2-positive breast cancerHigh lymphocytic infiltrationPositive breast cancerHER2-positive cancersImmune cell componentsNovel therapeutic optionsType breast cancerBreast cancer subtypesHost immunological responseImmunotherapeutic regimensClinical courseImmune markersLymphocytic infiltrationPositive cancersTherapeutic optionsInflammatory cellsClinical subtypingImmunological parametersClinical trialsImmune parametersImmunological response
2009
Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer.
Liedtke C, Yan K, Wu Y, Hortobagyi G, Symmans W, Valero V, Goette M, Kiesel L, Pusztai L. Targeting of breast cancer with non-oncology drugs – possible novel therapeutic option for triple-negative breast cancer. Cancer Research 2009, 69: 2119. DOI: 10.1158/0008-5472.sabcs-2119.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTherapeutic optionsCell linesEarly-stage breast cancerHuman triple-negative breast cancerCurrent chemotherapy agentsDrug targetsReceptor-positive cancersStage breast cancerBreast cancer cell line MCF-7Future therapeutic optionsNovel therapeutic optionsCancer cell line MCF-7TNBC cell linesBreast cancer cell linesGlutathione S-transferase piFine-needle biopsyDose-dependent inhibitionLack of ERCell line MCF-7Normal HER2 expressionCancer cell linesUnique drug targetsBiological presentation